CA2708679C - Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer - Google Patents

Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer Download PDF

Info

Publication number
CA2708679C
CA2708679C CA2708679A CA2708679A CA2708679C CA 2708679 C CA2708679 C CA 2708679C CA 2708679 A CA2708679 A CA 2708679A CA 2708679 A CA2708679 A CA 2708679A CA 2708679 C CA2708679 C CA 2708679C
Authority
CA
Canada
Prior art keywords
gemcitabine
treatment
formula
pancreatic cancer
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2708679A
Other languages
English (en)
French (fr)
Other versions
CA2708679A1 (en
Inventor
Lyne Gagnon
Lilianne Geerts
Christopher Penney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biosciences Inc
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of CA2708679A1 publication Critical patent/CA2708679A1/en
Application granted granted Critical
Publication of CA2708679C publication Critical patent/CA2708679C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2708679A 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer Active CA2708679C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
US61/008,129 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (2)

Publication Number Publication Date
CA2708679A1 CA2708679A1 (en) 2009-06-25
CA2708679C true CA2708679C (en) 2016-11-15

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2708679A Active CA2708679C (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Country Status (15)

Country Link
US (1) US8946190B2 (enExample)
EP (1) EP2231166B1 (enExample)
JP (1) JP5473937B2 (enExample)
KR (1) KR101603351B1 (enExample)
CN (1) CN101903028B (enExample)
AU (1) AU2008338204B2 (enExample)
BR (1) BRPI0821395A2 (enExample)
CA (1) CA2708679C (enExample)
DK (1) DK2231166T3 (enExample)
ES (1) ES2414617T3 (enExample)
MX (1) MX2010006867A (enExample)
NZ (1) NZ586249A (enExample)
PT (1) PT2231166E (enExample)
TW (1) TWI448290B (enExample)
WO (1) WO2009076761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526052A (ja) 2009-05-04 2012-10-25 プロメティック・バイオサイエンシーズ・インコーポレイテッド 置換芳香族化合物およびその薬学的使用
AU2011356583C1 (en) * 2010-10-27 2016-03-17 Liminal Biosciences Limited Compounds and compositions for the treatment of cancer
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP2956121B1 (en) 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
AU2014222389B2 (en) * 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US10463684B2 (en) 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
AU2019358595B2 (en) 2018-10-11 2025-04-17 Basf As Aromatic compounds and pharmaceutical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010441A1 (en) * 1989-03-13 1990-09-20 Thornfeldt Carl R Treatment of skin diseases and tumors
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
PT1900364E (pt) * 2001-04-18 2013-12-19 Prometic Biosciences Inc Ácidos gordos de cadeia de comprimento médio, glicéridos e análogos como fatores de sobrevivência e ativação de neutrófilos
AU2002329842B2 (en) 2001-08-29 2006-09-14 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
ES2255467T3 (es) * 2003-02-07 2009-05-01 Prometic Biosciences Inc. Acidos grasos de cadena de longitud media, gliceridos y analogos como estimuladores de eritropoyesis.
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
TW200934494A (en) 2009-08-16
EP2231166A1 (en) 2010-09-29
TWI448290B (zh) 2014-08-11
ES2414617T3 (es) 2013-07-22
DK2231166T3 (da) 2013-06-24
US8946190B2 (en) 2015-02-03
KR101603351B1 (ko) 2016-03-14
US20100273731A1 (en) 2010-10-28
PT2231166E (pt) 2013-06-17
BRPI0821395A2 (pt) 2015-06-16
JP5473937B2 (ja) 2014-04-16
HK1151244A1 (en) 2012-01-27
MX2010006867A (es) 2010-08-31
CN101903028B (zh) 2013-06-05
EP2231166B1 (en) 2013-03-20
WO2009076761A1 (en) 2009-06-25
CN101903028A (zh) 2010-12-01
AU2008338204A1 (en) 2009-06-25
EP2231166A4 (en) 2012-02-22
KR20100101134A (ko) 2010-09-16
JP2011506492A (ja) 2011-03-03
CA2708679A1 (en) 2009-06-25
NZ586249A (en) 2012-05-25
AU2008338204B2 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
CA2708679C (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
CA2319872C (en) Pharmaceutical composition for the treatment of hepatocellular carcinoma
TW201406371A (zh) 厚朴酚用於治療或預防膀胱癌生長和轉移及改善惡病質之新用途
CN115414351B (zh) pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用
WO2012075754A1 (zh) 一种治疗急性淋巴白血病的复方药物组合物
CN111514140B (zh) 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
CN116115623B (zh) 2'-岩藻糖基乳糖作为一种抗肿瘤辅助药物的应用
CN115135326B (zh) 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
CN113350325B (zh) 二蒽酮类化合物在制备抗肿瘤药物中的应用
HK1151244B (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
WO2022225045A1 (ja) グレリン抵抗性を伴う悪液質の治療剤又は予防剤
HU225988B1 (en) Use of cytidine-phosphocholine for producing pharmaceutical compositions for diabetic neuropathy
CA2191230C (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
CN111558045A (zh) 一种治疗肺癌的药物组合物
US20070269531A1 (en) Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer
CN113440534A (zh) 一种毛蕊花糖苷在制备药物中的应用
CN113244242A (zh) 甘草次酸、甘草酸在预防或治疗肺炎/肺纤维化中的应用
JP2024506336A (ja) 膠芽腫の治療方法
CN119015282A (zh) 一种甲基喹啉脲类化合物防治恶性肿瘤恶病质的用途
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
CN110876803A (zh) 一种包含乳蛋白和油酸的药物组合物
Yamagiwa et al. Hepatic arterial chemoembolization as an initial treatment for hepatoblastoma
WO2001058490A1 (en) Liver-selective chemotherapy
WO2009111555A1 (en) Combination treatment for bladder cancer comprisining valrubicin and trospium chloride

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131216